Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine
Author:
Publisher
Springer Nature Switzerland
Link
https://link.springer.com/content/pdf/10.1007/16833_2024_254
Reference177 articles.
1. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110–1122
2. Akanda M, Mithu MSH, Douroumis D (2023) Solid lipid nanoparticles: an effective lipid-based technology for cancer treatment. J Drug Deliv Sci Technol 104709
3. Al-Ziftawi NH, Alam MF, Elazzazy S, Shafie AA, Hamad A, Mohamed Ibrahim MI (2023) Cost-effectiveness and cost-utility of Palbociclib versus Ribociclib in women with stage IV breast cancer: a real-world data evaluation. Int J Environ Res Public Health 20:512
4. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B (2019) Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med 380:1929–1940
5. Arena F (2014) Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer. Cancer Manag Res 389–395
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3